170 related articles for article (PubMed ID: 35267618)
21. CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities-Merits and Challenges.
Harrer DC; Dörrie J; Schaft N
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31779130
[TBL] [Abstract][Full Text] [Related]
22. The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma.
Simon B; Wiesinger M; März J; Wistuba-Hamprecht K; Weide B; Schuler-Thurner B; Schuler G; Dörrie J; Uslu U
Int J Mol Sci; 2018 Aug; 19(8):. PubMed ID: 30103488
[TBL] [Abstract][Full Text] [Related]
23. PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas.
Bertucci F; Finetti P; Perrot D; Leroux A; Collin F; Le Cesne A; Coindre JM; Blay JY; Birnbaum D; Mamessier E
Oncoimmunology; 2017; 6(3):e1278100. PubMed ID: 28405501
[TBL] [Abstract][Full Text] [Related]
24. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
Poli A; Wang J; Domingues O; Planagumà J; Yan T; Rygh CB; Skaftnesmo KO; Thorsen F; McCormack E; Hentges F; Pedersen PH; Zimmer J; Enger PØ; Chekenya M
Oncotarget; 2013 Sep; 4(9):1527-46. PubMed ID: 24127551
[TBL] [Abstract][Full Text] [Related]
25. Effects of chondroitin sulfate proteoglycan 4 (NG2/CSPG4) on soft-tissue sarcoma growth depend on tumor developmental stage.
Hsu SC; Nadesan P; Puviindran V; Stallcup WB; Kirsch DG; Alman BA
J Biol Chem; 2018 Feb; 293(7):2466-2475. PubMed ID: 29196603
[TBL] [Abstract][Full Text] [Related]
26. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma.
Price MA; Colvin Wanshura LE; Yang J; Carlson J; Xiang B; Li G; Ferrone S; Dudek AZ; Turley EA; McCarthy JB
Pigment Cell Melanoma Res; 2011 Dec; 24(6):1148-57. PubMed ID: 22004131
[TBL] [Abstract][Full Text] [Related]
27. Immune-infiltration based signature as a novel prognostic biomarker in gastrointestinal stromal tumour.
Wei ZW; Wu J; Huang WB; Li J; Lu XF; Yuan YJ; Xiong WJ; Zhang XH; Wang W; He YL; Zhang CH
EBioMedicine; 2020 Jul; 57():102850. PubMed ID: 32574962
[TBL] [Abstract][Full Text] [Related]
28. Risk stratification systems for surgically treated localized primary Gastrointestinal Stromal Tumors (GIST). Review of literature and comparison of the three prognostic criteria: MSKCC Nomogramm, NIH-Fletcher and AFIP-Miettinen.
Belfiori G; Sartelli M; Cardinali L; Tranà C; Bracci R; Gesuita R; Marmorale C
Ann Ital Chir; 2015; 86(3):219-27. PubMed ID: 26098671
[TBL] [Abstract][Full Text] [Related]
29. Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in
Hu ZY; Zheng C; Yang J; Ding S; Tian C; Xie N; Xue L; Wu M; Fu S; Rao Z; Price MA; McCarthy JB; Ouyang Q; Lin J; Deng X
Front Oncol; 2022; 12():804466. PubMed ID: 35280756
[TBL] [Abstract][Full Text] [Related]
30. Genomic Grade Index predicts postoperative clinical outcome of GIST.
Bertucci F; Finetti P; Ostrowski J; Kim WK; Kim H; Pantaleo MA; Astolfi A; Polkowski M; Birnbaum D
Br J Cancer; 2012 Oct; 107(8):1433-41. PubMed ID: 22929880
[TBL] [Abstract][Full Text] [Related]
31. Characteristics and prognosis of jejunoileal gastrointestinal stromal tumours (GISTs) in the era of imatinib: a comparative study with gastric GISTs.
Fernández JA; Ferreras D; Ruiz-Manzanera JJ; Olivares V; Ferri B; Frutos MD; Martínez J
Clin Transl Oncol; 2021 Jul; 23(7):1368-1376. PubMed ID: 33515420
[TBL] [Abstract][Full Text] [Related]
32. miR-125a-5p regulation increases phosphorylation of FAK that contributes to imatinib resistance in gastrointestinal stromal tumors.
Huang WK; Akçakaya P; Gangaev A; Lee L; Zeljic K; Hajeri P; Berglund E; Ghaderi M; Åhlén J; Bränström R; Larsson C; Lui WO
Exp Cell Res; 2018 Oct; 371(1):287-296. PubMed ID: 30149002
[TBL] [Abstract][Full Text] [Related]
33. Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance.
Wiesinger M; März J; Kummer M; Schuler G; Dörrie J; Schuler-Thurner B; Schaft N
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31426437
[TBL] [Abstract][Full Text] [Related]
34. [Clinicopathological features and prognosis of gastrointestinal stromal tumor with PDGFRA-D842V mutation].
Li XQ; Tu L; Wang M; Ma XL; Yang LX; Shen YY; Zhuang C; Zhao WY; Qiu JF; Zhao G; Cao H
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):872-879. PubMed ID: 32927512
[No Abstract] [Full Text] [Related]
35. [Targeted therapy combined with immunotherapy in gastrointestinal stromal tumor: a new era of hope and challenges].
Zhao W; Cao H
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):966-971. PubMed ID: 28900984
[TBL] [Abstract][Full Text] [Related]
36. NK cells and ILCs in tumor immunotherapy.
Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
[TBL] [Abstract][Full Text] [Related]
37. The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma.
Simon B; Harrer DC; Schuler-Thurner B; Schaft N; Schuler G; Dörrie J; Uslu U
Exp Dermatol; 2018 Jul; 27(7):769-778. PubMed ID: 29704887
[TBL] [Abstract][Full Text] [Related]
38.
Billon E; Finetti P; Bertucci A; Niccoli P; Birnbaum D; Mamessier E; Bertucci F
Oncoimmunology; 2019; 8(11):e1655362. PubMed ID: 31646101
[TBL] [Abstract][Full Text] [Related]
39. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis.
Hassan I; You YN; Shyyan R; Dozois EJ; Smyrk TC; Okuno SH; Schleck CD; Hodge DO; Donohue JH
Ann Surg Oncol; 2008 Jan; 15(1):52-9. PubMed ID: 18000711
[TBL] [Abstract][Full Text] [Related]
40. In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment.
Grote S; Ureña-Bailén G; Chan KC; Baden C; Mezger M; Handgretinger R; Schleicher S
Cells; 2021 Apr; 10(5):. PubMed ID: 33925968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
